These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 30222699)
1. Recruitment and Engagement in Preventive Clinical Trials: Interdependencies and Mediation. Ollivier-Yaniv C J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S3-S7. PubMed ID: 30222699 [TBL] [Abstract][Full Text] [Related]
2. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand. Jenkins RA; Chinaworapong S; Morgan PA; Ruangyuttikarn C; Sontirat A; Chiu J; Michael RA; Nitayaphan S; Khamboonruang C J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):171-7. PubMed ID: 9637582 [TBL] [Abstract][Full Text] [Related]
3. Logics of Commitment in Vaccine Trials of the ANRS Cohorts 1992-2001. Fillieule O J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S59-S68. PubMed ID: 30222706 [TBL] [Abstract][Full Text] [Related]
4. Contextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials. Doshi M; Avery L; Kaddu RP; Gichuhi M; Gakii G; du Plessis E; Dutta S; Khan S; Kimani J; Lorway RR BMC Public Health; 2017 May; 17(1):469. PubMed ID: 28521748 [TBL] [Abstract][Full Text] [Related]
5. Being "False Positive": An "Inconvenience"? Debates and Questions Regarding the Notion of Vaccine-Induced Seropositivity (VISP) in the Recruitment of Healthy Volunteers for a Preventive Anti-HIV Vaccine Trial. Couderc M J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S20-S29. PubMed ID: 30222702 [TBL] [Abstract][Full Text] [Related]
7. To report or not to report: Exploring healthy volunteers' rationales for disclosing adverse events in Phase I drug trials. McManus L; Fisher JA AJOB Empir Bioeth; 2018; 9(2):82-90. PubMed ID: 29693508 [TBL] [Abstract][Full Text] [Related]
9. Motivators to participation in actual HIV vaccine trials. Dhalla S; Poole G AIDS Behav; 2014 Feb; 18(2):263-77. PubMed ID: 23736885 [TBL] [Abstract][Full Text] [Related]
10. Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. O'Connell JM; Hogg RS; Chan K; Strathdee SA; McLean N; Martindale SL; Willoughby B; Remis R J Acquir Immune Defic Syndr; 2002 Dec; 31(5):521-8. PubMed ID: 12473841 [TBL] [Abstract][Full Text] [Related]
11. Provision of HIV treatment in HIV preventive vaccine trials: a developing country perspective. Slack C; Stobie M; Milford C; Lindegger G; Wassenaar D; Strode A; Ijsselmuiden C Soc Sci Med; 2005 Mar; 60(6):1197-208. PubMed ID: 15626517 [TBL] [Abstract][Full Text] [Related]
12. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082 [TBL] [Abstract][Full Text] [Related]
13. Does an HIV clinical trial information booklet improve patient knowledge and understanding of HIV clinical trials? Ives NJ; Troop M; Waters A; Davies S; Higgs C; Easterbrook PJ HIV Med; 2001 Oct; 2(4):241-9. PubMed ID: 11737404 [TBL] [Abstract][Full Text] [Related]
14. More than the money: a review of the literature examining healthy volunteer motivations. Stunkel L; Grady C Contemp Clin Trials; 2011 May; 32(3):342-52. PubMed ID: 21146635 [TBL] [Abstract][Full Text] [Related]
15. Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein. Luzi AM; Gallo P; Colucci A; Marcotullio S; Bellino S; Longo O; Ensoli B AIDS Care; 2011 Aug; 23(8):939-46. PubMed ID: 21390884 [TBL] [Abstract][Full Text] [Related]
16. Motivators to participation in medical trials: the application of social and personal categorization. Dhalla S; Poole G Psychol Health Med; 2013; 18(6):664-75. PubMed ID: 23360313 [TBL] [Abstract][Full Text] [Related]
17. Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials. Manton KJ; Gauld CS; White KM; Griffin PM; Elliott SL BMJ Open; 2019 Jan; 9(1):e024224. PubMed ID: 30647042 [TBL] [Abstract][Full Text] [Related]
18. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention. Allen M; Lau CY Soc Sci Med; 2008 Feb; 66(4):945-51. PubMed ID: 18162272 [TBL] [Abstract][Full Text] [Related]
19. Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial. Cattapan A; Browne K; Halperin DM; Di Castri A; Fullsack P; Graham J; Langley JM; Taylor BA; McNeil SA; Halperin SA Vaccine; 2019 Jan; 37(2):289-295. PubMed ID: 30528592 [TBL] [Abstract][Full Text] [Related]